Watson Biologics Halts Recombinant COVID-19 Vaccine Development; Sumitomo Pharma Establishes Trading Subsidiary in China
Walvax
Human Vaccine Research and Development, Manufacturer
Junshi Biosciences
Innovative Drug Developer
Bio-Raid
CAR-T Immune Cell Drug Developer
The Development of COVID-19 Vaccines Needs to Cut Losses.
On April 24, Walvax Biotechnology Co., Ltd. announced that the company has decided to terminate the clinical trial of the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector) developed by its wholly-owned subsidiary, Beijing Weidai Biotechnology Co., Ltd.
Foreign pharmaceutical companies continue to deepen their presence in China.
Today, Sumitomo Dainippon Pharma (China) Investment Co., Ltd. announced the establishment of its wholly-owned subsidiary, Sumitomo Dainippon Pharma Trading (Suzhou) Co., Ltd., which will handle the import and sales of finished pharmaceutical products while providing warehousing, storage, and logistics services.
Roche Releases Q1 Report.
On April 24, Roche's Q1 2024 financial report showed total revenue of CHF 14.399 billion, growing by 2% at constant exchange rates. Excluding COVID-19 related products, sales increased by 7%. What is your take on this performance?
What are the hot topics in the pharmaceutical market in China and abroad that are worth paying attention to in the past day? Let Amino take you through them.
/ 01 /
Market Express
1) Sumitomo Pharma Announces Establishment of Trading Company in China
On April 24, Sumitomo Pharma Investments (China) Co., Ltd. announced the establishment of its wholly-owned subsidiary, Sumitomo Pharma Trading (Suzhou) Co., Ltd., which is responsible for the import and sales of finished pharmaceutical products, as well as providing warehousing, storage, and logistics services.
/ 02 /
Pharmaceuticals and Medical Devices Dynamics
1) Chongqing Yuyan Pharmaceutical Co., Ltd.'s Recombinant Type A Botulinum Toxin First Global Medical Indication IND Application Accepted by CDE
On April 24, Innovent Biologics announced that the first medical indication for adult upper limb muscle spasticity of its innovative recombinant botulinum toxin type A, independently developed by its holding company Chongqing Yuyan Pharmaceutical Co., Ltd. with global intellectual property rights, has been officially accepted by the CDE.
2) Walvax Biotechnology Co.,Ltd. Terminates Clinical Trial of Recombinant Novel Coronavirus Vaccine (Chimpanzee Adenovirus Vector)
On April 24, Walvax Biotechnology Co., Ltd. announced that the company has decided to terminate the clinical trial of the recombinant novel coronavirus vaccine (chimpanzee adenovirus vector) developed by its wholly-owned subsidiary, Beijing Weida Biotechnology Co., Ltd.
3) Junshi Biosciences' Toripalimab Marketing Authorization Application Accepted by the Drug Office of the Hong Kong Department of Health
On April 24, Junshi Biosciences announced that the marketing authorization application for toripalimab in combination with cisplatin/gemcitabine as a first-line treatment for adult patients with metastatic or recurrent locally advanced nasopharyngeal carcinoma, and as a monotherapy for adult patients with recurrent, unresectable, or metastatic nasopharyngeal carcinoma who have progressed during or after prior platinum-containing therapy, has been accepted by the Drug Office of the Hong Kong Department of Health.
4) Betta Pharmaceuticals' BPI-16350 Obtains Phase III Clinical Trial Summary Report
On April 24, Betta Pharmaceuticals announced that after completing the Phase III clinical trial of its self-developed project BPI-16350 (Tebecil Tartrate Capsules), a clinical trial summary report has been obtained following a series of statistical analysis work.
5) Bio-Raid's CD99-targeted CAR-T Cell Injection Approved for Clinical Trials
On April 24, according to the CDE official website, Bio-Raid's CD99-targeted chimeric antigen receptor gene-modified autologous T-cell injection has been approved for clinical trials. It is intended for the study of treating patients aged ≥18 years with recurrent/refractory CD99+ bone or soft tissue sarcoma.
6) Highchem Bio WGI-0301 Approved for Clinical Trials
On April 24, according to the CDE website, WGI-0301 from HaiChang Biotech was approved for clinical trials, intended to conduct research on the treatment of advanced hepatocellular carcinoma.
7) Xinyi Pharmaceutical's Dexmedetomidine Hydrochloride Microneedle Patch Approved for Clinical Trials
On April 24, according to the CDE official website, Xinyi Pharmaceutical's Dexmedetomidine Hydrochloride Microneedle Patch was approved for clinical trials, intended for preoperative sedation in children.
8) Akeso Cadonilimab New Indication Submission for Market Approval
On April 24, Akeso Biopharma announced that the CDE has accepted the new indication application for Cadonilimab, a PD-1/CTLA-4 bispecific antibody, for use in combination with platinum-based chemotherapy with or without Bevacizumab as a first-line treatment for persistent, recurrent, or metastatic cervical cancer.
/ 03 /
Overseas Pharmaceutical News
1) Roche Announces Q1 Earnings Report
On April 24, Roche released its Q1 2024 financial report. During the reporting period, the company's total revenue was 14.399 billion Swiss francs, representing a 2% increase at constant exchange rates. Excluding COVID-19 related products, sales grew by 7%.
2) Incyte Acquires Escient and Its Assets
On April 23, Incyte announced that it would acquire Escient, which focuses on inflammatory diseases, and its assets for $750 million, plus the remaining net cash of Escient at the closing of the transaction.
Text / Huang Kai
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
